Keros Therapeutics, Inc. - Common Stock (KROS)
CUSIP: 492327101
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 19,711,307
- Total 13F shares
- 32,796,190
- Share change
- -3,955,035
- Total reported value
- $334,208,916
- Put/Call ratio
- 139%
- Price per share
- $10.19
- Number of holders
- 154
- Value change
- -$101,548,195
- Number of buys
- 92
- Number of sells
- 90
Quarterly Holders Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 492327101:
Top shareholders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
1.7%
from 13D/G
|
5,543,308
|
$87,750,559 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
14%
|
2,729,278
|
$43,204,469 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
9.9%
|
1,957,109
|
$30,981,036 | — | 31 Dec 2024 | |
| BRAIDWELL LP |
13F
|
Company |
9.6%
|
1,894,439
|
$29,988,969 | — | 31 Dec 2024 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
8.6%
|
1,687,135
|
$26,707,347 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
6.1%
|
1,203,383
|
$19,049,553 | — | 31 Dec 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
6.1%
|
1,199,990
|
$18,995,842 | — | 31 Dec 2024 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
13D/G
|
Company |
2.7%
from 13D/G
|
1,101,000
|
$17,428,830 | — | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
5.2%
|
1,018,734
|
$16,126,559 | — | 31 Dec 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
4.6%
|
915,048
|
$14,485,210 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
4.6%
|
909,707
|
$14,402,000 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
4.5%
|
878,159
|
$13,901,257 | — | 31 Dec 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.4%
|
866,737
|
$13,720,447 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4%
|
791,109
|
$12,523,256 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.9%
|
765,436
|
$12,119,808 | — | 31 Dec 2024 | |
| MANGROVE PARTNERS IM, LLC |
13F
|
Company |
3.7%
|
736,385
|
$11,656,975 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
3.3%
|
656,801
|
$10,397,174 | — | 31 Dec 2024 | |
| Redmile Group, LLC |
13F
|
Company |
2.8%
|
552,506
|
$8,746,170 | — | 31 Dec 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.8%
|
550,000
|
$8,706,500 | — | 31 Dec 2024 | |
| Lynx1 Capital Management LP |
13F
|
Company |
2.8%
|
544,001
|
$8,611,536 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.7%
|
535,584
|
$8,478,295 | — | 31 Dec 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
2.3%
|
450,000
|
$7,123,500 | — | 31 Dec 2024 | |
| Catalio Capital Management, LP |
13F
|
Company |
2.1%
|
407,292
|
$6,447,432 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
2%
|
387,701
|
$6,137,307 | — | 31 Dec 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
380,000
|
$6,015,400 | — | 31 Dec 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.7%
|
328,920
|
$5,206,816 | — | 31 Dec 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.6%
|
314,541
|
$4,979,184 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.5%
|
296,467
|
$4,693,073 | — | 31 Dec 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.5%
|
288,428
|
$4,565,815 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.4%
|
279,682
|
$4,427,366 | — | 31 Dec 2024 | |
| Jennifer Lachey |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
103,855
mixed-class rows
|
$4,307,079 | — | 15 Jul 2022 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.3%
|
250,000
|
$3,957,500 | — | 31 Dec 2024 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
1.2%
|
244,633
|
$3,872,540 | — | 31 Dec 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
1.2%
|
242,633
|
$3,840,880 | — | 31 Dec 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.1%
|
221,391
|
$3,504,620 | — | 31 Dec 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
1.1%
|
216,103
|
$3,420,910 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
213,431
|
$3,378,613 | — | 31 Dec 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.1%
|
211,309
|
$3,345,021 | — | 31 Dec 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
1.1%
|
210,000
|
$3,324,300 | — | 31 Dec 2024 | |
| Walleye Capital LLC |
13F
|
Company |
1%
|
197,666
|
$3,129,053 | — | 31 Dec 2024 | |
| Clearbridge Investments, LLC |
13F
|
Company |
0.96%
|
190,064
|
$3,008,711 | — | 31 Dec 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
0.95%
|
187,500
|
$2,968,125 | — | 31 Dec 2024 | |
| Altium Capital Management LLC |
13F
|
Company |
0.89%
|
175,000
|
$2,770,250 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.89%
|
174,941
|
$2,769,316 | — | 31 Dec 2024 | |
| Christopher Rovaldi |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
60,000
|
$2,640,600 | — | 18 Feb 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.82%
|
161,467
|
$2,556,023 | — | 31 Dec 2024 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
0.79%
|
155,347
|
$2,459,143 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.79%
|
155,163
|
$2,456,024 | — | 31 Dec 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.7%
|
137,424
|
$2,175,422 | — | 31 Dec 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.66%
|
130,316
|
$2,062,902 | — | 31 Dec 2024 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q1 2025
As of 31 Mar 2025,
Keros Therapeutics, Inc. - Common Stock (KROS) was held by
154 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,796,190 shares.
The largest 10 holders included
BlackRock, Inc., JPMORGAN CHASE & CO, VANGUARD GROUP INC, Logos Global Management LP, MORGAN STANLEY, Nantahala Capital Management, LLC, ADAR1 Capital Management, LLC, STATE STREET CORP, D. E. Shaw & Co., Inc., and FEDERATED HERMES, INC..
This page lists
154
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
159
Q1 2025 holders
154
Holder diff
-5
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.